Isotopic decay of urinary or plasma 3-methylhistidine as a potential biomarker of pathologic skeletal muscle loss

Journal of Cachexia, Sarcopenia and Muscle

Volumn 5, Issue 1, 2014, Pages 19-25

  Sheffield Moore, M ^a   Dillon, E L ^a   Randolph, K M ^a   Casperson, S L ^a   White, G R ^a   Jennings, K ^a   Rathmacher, J ^b   Schuette, S ^c   Janghorbani, M ^c   Urban, R J ^a   Hoang, V ^a   Willis, M ^a   Durham, W J ^a  

^a UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

^b Metabolic Technologies Incorporated   (United States)

^c Biochemanalysis Corporation   (United States)

Author keywords

Cachexia; Human; Sarcopenia; Tracer

Indexed keywords

3 METHYLHISTIDINE; MUSCLE PROTEIN;

ADULT; AGE; ARTICLE; BIOCHEMICAL COMPOSITION; CALORIC INTAKE; CARBOHYDRATE INTAKE; CONTROLLED STUDY; DIET RESTRICTION; DIETARY INTAKE; FAT INTAKE; FEASIBILITY STUDY; HUMAN; HUMAN EXPERIMENT; ISOTOPE LABELING; MACRONUTRIENT; MALE; MEAL; MEAT; MYOPATHY; NORMAL HUMAN; PLASMA; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN INTAKE; RADIOISOTOPE DECAY; SAMPLING; SKELETAL MUSCLE LOSS; URINALYSIS; URINE;

EID: 84896357087     PISSN: 21905991     EISSN: 21906009     Source Type: Journal    
DOI: 10.1007/s13539-013-0117-7     Document Type: Article

References (55)

1. Evans WJ. Skeletal muscle loss: cachexia, sarcopenia, and inactivity. Am J Clin Nutr. 2010;91: 1123S-7.
2. Fielding RA et al. Sarcopenia: an undiagnosed condition in older adults. Current consensus definition: prevalence, etiology, and consequences. International Working Group on Sarcopenia. J Am Med Dir Assoc. 2011;12: 249-56.
3. Hughes VA, Frontera WR, Roubenoff R, Evans WJ, Singh MA. Longitudinal changes in body composition in older men and women: role of body weight change and physical activity. Am J Clin Nutr. 2002;76: 473-81.
4. Morley JE, Abbatecola AM, Argiles JM, Baracos V, Bauer J, Bhasin S, et al. Sarcopenia with limited mobility: an international consensus. J Am Med Dir Assoc. 2011;12: 403-9.
5. Lauretani F, Russo CR, Bandinelli S, Bartali B, Cavazzini C, Di Iorio A, et al. Age-associated changes in skeletal muscles and their effect on mobility: an operational diagnosis of sarcopenia. J Appl Physiol. 2003;95: 1851-60.
6. Berg HE, Dudley GA, Haggmark T, Ohlsen H, Tesch PA. Effects of lower limb unloading on skeletal muscle mass and function in humans. J Appl Physiol. 1991;70: 1882-5.
7. Ferrando AA, Paddon-Jones D, Wolfe RR. Bed rest and myopathies. Curr Opin Clin Nutr Metab Care. 2006;9: 410-5.
8. Paddon-Jones D, Sheffield-Moore M, Cree MG, Hewlings SJ, Aarsland A, Wolfe RR, et al. Atrophy and impaired muscle protein synthesis during prolonged inactivity and stress. J Clin Endocrinol Metab. 2006;91: 4836-41.
9. Paddon-Jones D, Sheffield-Moore M, Urban RJ, Aarsland A, Wolfe RR, Ferrando AA. The catabolic effects of prolonged inactivity and acute hypercortisolemia are offset by dietary supplementation. J Clin Endocrinol Metab. 2005;90: 1453-9.
10. Berg HE, Eiken O, Miklavcic L, Mekjavic IB. Hip, thigh and calf muscle atrophy and bone loss after 5-week bedrest inactivity. Eur J Appl Physiol. 2007;99: 283-9.
11. Brooks N, Cloutier GJ, Cadena SM, Layne JE, Nelsen CA, Freed AM, et al. Resistance training and timed essential amino acids protect against the loss of muscle mass and strength during 28 days of bed rest and energy deficit. J Appl Physiol. 2008;105: 241-8.
12. Coker RH, Wolfe RR. Bedrest and sarcopenia. Curr Opin Clin Nutr Metab Care. 2012;15: 7-11.
13. English KL, Paddon-Jones D. Protecting muscle mass and function in older adults during bed rest. Curr Opin Clin Nutr Metab Care. 2010;13: 34-9.
14. Durham WJ, Dillon EL, Sheffield-Moore M. Inflammatory burden and amino acid metabolism in cancer cachexia. Curr Opin Clin Nutr Metab Care. 2009;12: 72-7.
15. Tisdale MJ. Cancer cachexia. Curr Opin Gastroenterol. 2010;26: 146-51.
16. Tisdale MJ. Mechanisms of cancer cachexia. Physiol Rev. 2009;89: 381-410.
17. Fearon K, Strasser F, Anker SD, Bosaeus I, Bruera E, Fainsinger RL, et al. Definition and classification of cancer cachexia: an international consensus. Lancet Oncol. 2011;12: 489-95.
18. Fearon KC. Cancer cachexia and fat-muscle physiology. N Engl J Med. 2011;365: 565-7.
19. Tan BH, Fearon KC. Cachexia: prevalence and impact in medicine. Curr Opin Clin Nutr Metab Care. 2008;11: 400-7.
20. Argiles JM, Busquets S, Lopez-Soriano FJ. Anti-inflammatory therapies in cancer cachexia. Eur J Pharmacol. 2011;668 Suppl 1: S81-6.
21. Argiles JM, Olivan M, Busquets S, Lopez-Soriano FJ. Optimal management of cancer anorexia-cachexia syndrome. Cancer Manag Res. 2010;2: 27-38.
22. Buford TW, Lott DJ, Marzetti E, Wohlgemuth SE, Vandenborne K, Pahor M, et al. Age-related differences in lower extremity tissue compartments and associations with physical function in older adults. Exp Gerontol. 2012;47: 38-44.
23. Marzetti E, Lees HA, Manini TM, Buford TW, Aranda Jr JM, Calvani R, et al. Skeletal muscle apoptotic signaling predicts thigh muscle volume and gait speed in community-dwelling older persons: an exploratory study. PLoS One. 2012;7: e32829.
24. Joseph AM, Adhihetty PJ, Buford TW, Wohlgemuth SE, Lees HA, Nguyen LM, et al. The impact of aging on mitochondrial function and biogenesis pathways in skeletal muscle of sedentary high- and low-functioning elderly individuals. Aging Cell. 2012;11(5): 801-9.
25. Phillips SM. Nutrient-rich meat proteins in offsetting age-related muscle loss. Meat Sci. 2012;92(3): 174-8.
26. Fearon KC, Voss AC, Hustead DS. Definition of cancer cachexia: effect of weight loss, reduced food intake, and systemic inflammation on functional status and prognosis. Am J Clin Nutr. 2006;83: 1345-50.
27. Kimyagarov S, Klid R, Fleissig Y, Kopel B, Arad M, Adunsky A. Skeletal muscle mass abnormalities are associated with survival rates of institutionalized elderly nursing home residents. J Nutr Health Aging. 2012;16: 432-6.
28. Tisdale MJ. Cachexia in cancer patients. Nat Rev Cancer. 2002;2: 862-71.
29. Lee SJ, Glass DJ. Treating cancer cachexia to treat cancer. Skelet Muscle. 2011;1: 2.
30. Tisdale MJ. Reversing cachexia. Cell. 2010;142: 511-2.
31. Benny Klimek ME, Aydogdu T, Link MJ, Pons M, Koniaris LG, Zimmers TA. Acute inhibition of myostatin-family proteins preserves skeletal muscle in mouse models of cancer cachexia. Biochem Biophys Res Commun. 2010;391: 1548-54.
32. Zhou X, Wang JL, Lu J, Song Y, Kwak KS, Jiao Q, et al. Reversal of cancer cachexia and muscle wasting by ActRIIB antagonism leads to prolonged survival. Cell. 2010;142: 531-43.
33. Dillon EL, Volpi E, Wolfe RR, Sinha S, Sanford AP, Arrastia CD, et al. Amino acid metabolism and inflammatory burden in ovarian cancer patients undergoing intense oncological therapy. Clin Nutr. 2007;26: 736-43.
34. Phillips BE, Hill DS, Atherton PJ. Regulation of muscle protein synthesis in humans. Curr Opin Clin Nutr Metab Care. 2012;15: 58-63.
35. Deutz NE, Safar A, Schutzler S, Memelink R, Ferrando A, Spencer H, et al. Muscle protein synthesis in cancer patients can be stimulated with a specially formulated medical food. Clin Nutr. 2011;30: 759-68.
36. Breen L, Phillips SM. Skeletal muscle protein metabolism in the elderly: interventions to counteract the 'anabolic resistance' of ageing. Nutr Metab (Lond). 2011;8: 68.
37. Cuthbertson D, Smith K, Babraj J, Leese G, Waddell T, Atherton P, et al. Anabolic signaling deficits underlie amino acid resistance of wasting, aging muscle. FASEB J. 2005;19: 422-4.
38. Rennie MJ. Anabolic resistance: the effects of aging, sexual dimorphism, and immobilization on human muscle protein turnover. Appl Physiol Nutr Metab. 2009;34: 377-81.
39. Elzinga M, Collins JH, Kuehl WM, Adelstein RS. Complete amino-acid sequence of actin of rabbit skeletal muscle. Proc Natl Acad Sci U S A. 1973;70: 2687-91.
40. Huszar G, Elzinga M. Amino acid sequence around the single 3-methylhistidine residue in rabbit skeletal muscle myosin. Biochemistry. 1971;10: 229-36.
41. Bilmazes C, Uauy R, Haverberg LN, Munro HN, Young VR. Musle protein breakdown rates in humans based on Ntau-methylhistidine (3-methylhistidine) content of mixed proteins in skeletal muscle and urinary output of Ntau-methylhistidine. Metabolism. 1978;27: 525-30.
42. Young VR, Munro HN. Ntau-methylhistidine (3-methylhistidine) and muscle protein turnover: an overview. Fed Proc. 1978;37: 2291-300.
43. Young VR, Alexis SD, Baliga BS, Munro HN, Muecke W. Metabolism of administered 3-methylhistidine. Lack of muscle transfer ribonucleic acid charging and quantitative excretion as 3-methylhistidine and its N-acetyl derivative. J Biol Chem. 1972;247: 3592-600.
44. Long CL, Haverberg LN, Young VR, Kinney JM, Munro HN, Geiger JW. Metabolism of 3-methylhistidine in man. Metabolism. 1975;24: 929-35.
45. Beffa DC, Carter EA, Lu XM, Yu YM, Prelack K, Sheridan RL, et al. Negative chemical ionization gas chromatography/mass spectrometry to quantify urinary 3-methylhistidine: application to burn injury. Anal Biochem. 2006;355: 95-101.
46. Campbell WW, Crim MC, Young VR, Joseph LJ, Evans WJ. Effects of resistance training and dietary protein intake on protein metabolism in older adults. Am J Physiol. 1995;268: E1143-53.
47. Fielding RA, Meredith CN, O'Reilly KP, Frontera WR, Cannon JG, Evans WJ. Enhanced protein breakdown after eccentric exercise in young and older men. J Appl Physiol. 1991;71: 674-9.
48. Trappe T, Williams R, Carrithers J, Raue U, Esmarck B, Kjaer M, et al. Influence of age and resistance exercise on human skeletal muscle proteolysis: a microdialysis approach. J Physiol. 2004;554: 803-13.
49. Rathmacher JA, Flakoll PJ, Nissen SL. A compartmental model of 3-methylhistidine metabolism in humans. Am J Physiol. 1995;269: E193-8.
50. Rathmacher JA, Link GA, Flakoll PJ, Nissen SL. Gas chromatographic/mass spectrometric analysis of stable isotopes of 3-methylhistidine in biological fluids: application to plasma kinetics in vivo. Biol Mass Spectrom. 1992;21: 560-6.
51. Cesari M, Fielding RA, Pahor M, Goodpaster B, Hellerstein M, van Kan GA, et al. Biomarkers of sarcopenia in clinical trials-recommendations from the International Working Group on Sarcopenia. J Cachexia Sarcopenia Muscle. 2012;3: 181-90.
52. Nedergaard A, Karsdal MA, Sun S, Henriksen K. Serological muscle loss biomarkers: an overview of current concepts and future possibilities. J Cachexia Sarcopenia Muscle. 2013;4: 1-17.
53. Scharf G, Heineke J. Finding good biomarkers for sarcopenia. J Cachexia Sarcopenia Muscle. 2012;3: 145-8.
54. Stimpson SA, Turner SM, Clifton LG, Poole JC, Mohammed HA, Shearer TW, et al. Total-body creatine pool size and skeletal muscle mass determination by creatine-(methyl-D3) dilution in rats. J Appl Physiol. 2012;112: 1940-8.
55. Stephens NA, Gallagher IJ, Rooyackers O, Skipworth RJ, Tan BH, Marstrand T, et al. Using transcriptomics to identify and validate novel biomarkers of human skeletal muscle cancer cachexia. Genome Med. 2010;2: 1.